Certain autonomous parvoviruses preferentially replicate in and kill in vitro-transformed cells and may reduce the incidence of spontaneous and implanted tumors in animals. Hence, these viruses and their derivatives are currently under evaluation as antitumor vectors. However, the mechanisms underlying their tumor-suppressing properties are not yet understood. We asked whether the lytic parvovirus H1 may enhance the immunogenicity of infected tumor cells. Out of human melanoma and gastrointestinal tumor cells, we selected the cell line SK29-Mel-1 being very susceptible to H1-induced apoptotic killing. Here, no upregulation of HLA class I and costimulatory molecules could be observed following H1 infection. However, a strong release of the immunogenic signal-the inducible heat-shock protein HSP72, but not constitutive HSP73-was observed after H1 infection. The HSP72 release was higher and of longer duration than a conventional heat-shock treatment. We also explored H1 replication and cytotoxicity in human immune cells, as such cells may constitute targets for H1 virus replication. Long-term cultured lymphocytes, monocytes, immature and mature dendritic cells were not susceptible to H1 virus. Altogether, parvovirus-mediated cell killing may in vivo enhance tumor immunogenicity by HSP72 release and thus contribute to the antitumor effect of parvoviruses.
C urrent anticancer strategies involve regimens increasing tumor cell death and enhancing tumor cell immune recognition. 1 As the immunogenicity of tumor cells is determined by specific tumor-associated antigens presented by the major histocompatibility complex (HLA) surface molecules, 2 new approaches aim to break tumor tolerance by liberating additional tumor antigens from tumor cell lysates. 3, 4 In particular, the immunogenicity of such tumor lysates has been attributed to heat-shock proteins (HSPs) and their complexed antigenic peptides, which are chaperoned into antigen-presenting cells (APC) and presented to cytotoxic T lymphocytes (CTL) stimulating the innate or adaptive immune system. [3] [4] [5] [6] [7] Oncolytic viruses may be of special interest as antitumor agents as they may enhance both, cell death and immunogenicity of tumors. 1, 8 Certain autonomously growing rodent parvoviruses (i.e. MVM and H1), hereafter referred to as parvoviruses, have been shown to reduce the incidence of spontaneous, chemically induced and xenografted tumors in laboratory animals. 8 These viruses also preferentially replicate in and kill human and rodent tumor cells in culture. Recombinant parvoviruses have been produced to transduce immunostimulatory cytokines and are currently under evaluation in several murine tumor models. 8, 9 However, the mechanisms underlying the parvovirus-induced antitumor effect are still unclear and seems to involve more than tumor cell killing. 10 We asked the question whether the oncolytic H1 is also able to enhance the immunogenicity of tumor cells. We selected the melanoma cell line SK29-Mel-l as it is highly susceptible to H1-induced killing from a collection of human melanoma and gastrointestinal tumor cells. The H1 infection of SK29-Mel-1 cells strongly induced the release of the inducible HSP72. Furthermore, we investigated the H1-induced killing and virus replication in human immune cells, to exclude undesired pathological effects on the immune system during parvovirus therapies.
Methods

Human tumor cells and primary immune cells
The melanoma cell lines MZ Mel 2, SK Mel 94, SK29-Mel-l and the gastrointestinal tumor cells MKN45 and LS1034 were propagated in Dulbecco's modified Eagle medium (Life Technologies, Karlsruhe, Germany). 5 Human CTL clones (CTL 2/9 and CTL IVSB) have been generated against the melanoma cell line SK29-Mel-1 from mixed lymphoid tissue culture populations from patient SK29. These cells and the EBV-transformed B cell line (MZ-EBV-B) were obtained as a gift from T. Woelfel, Mainz. Monocytes (PBMC) immature and mature dendritic cells (DC) were prepared from healthy donor buffy coats. 8 H1-induced cytotoxicity was determined postinfection (p.i.) by viability staining and ELISA reader, and by lactate dehydrogenase enzyme (LDH) activities of cell supernatants. 8 Cell death was analyzed by FACScan with Annexin V and propidium iodide and Cell Quest (BD, Heidelberg, Germany). 8 For transient H1 virus expression, infections were performed with the recombinant hH1D1600luc carrying the firefly luciferase-coding gene (luc) instead of capsid proteins. Cells were analyzed with a Luminometer (Berthold, Bad Wildbad, Germany). 8 For H1 protein detection, blot incubation was performed with the polyclonal antibody SP7 directed against the viral nonstructural protein NS1, and quantified by ChemiImager 5500. 8 For HSP analysis, monoclonal antibodies against the human inducible HSP72 and constitutive HSP73 were used (StressGen, Victoria, Canada). To induce heat shock in controls, tumor cells were incubated for 2 h at 421C. 5 To quantify HSP72, the specific HSP70 enzyme immunoassay was used (StressGen, Victoria, Canada).
Results and discussion
We first assessed several human melanoma or gastrointestinal tumor cell lines as well as human immune cells for their capability to support H1 infection and cell killing by viability staining for up to 5 days p.i. (Table 1) . A sharp MOI-dependent reduction of cell survival was observed for the melanoma SK29-Mel-1 and the gastrointestinal tumor cell line MKN45 compared with the noninfected control. After 5 days p.i., the viability of H1 virus-infected SK29-Mel-l (MOI ¼ 20) was decreased to less than 10%. The two other human melanoma (MZ Mel 2 and SK Mel 94) and LS1034 cells were less H1-sensitive than the SK29-Mel-1 cells. Since H1 virusinfected hepatoma cells were shown to display morphological features of apoptosis, 8 we evaluated the type of cell death in the above-cited cells by FACScan and Annexin V staining (Fig 1a) . In agreement with the viability assay, an increased number of dead cells was found in the SK29-Mel-1 and MKN45 cells. At day 3 p.i., more than 50% of H1-infected SK29-Mel-1 cells (MOI ¼ 20) were apoptotic. The H1-induced apoptosis was less extensive or undetectable for the other melanoma, MKN45 or LS1034 cells, respectively (Table 1) . To correlate parvoviral protein synthesis with H1-induced cell death, NS1 protein expression was determined by immunoblotting (Fig 1b) . Increasing NS1 amounts were observed in SK29-Mel-1 and MKN45 cell extracts for up to 3 days p.i. Extracts from LS1034 cells gave no significant NS1 levels. Viral gene expression was further analyzed by determining the luciferase activity with the vector hH1D1600luc. 8 Highest luciferase activities were found in SK29-Mel-1 cells 1-4 days p.i., at low MOI of 1 Â 10 À2 RU/cell. Hence, the general correlation of susceptibility to H1-induced cell killing with virus gene expression was found in agreement with published data. 8, 9 H1-induced cytotoxicity and transgene activity were also investigated in human immune cells. Lymphocytes, monocytes, immature and mature DC were H1-infected (MOI ¼ 20) and the numbers of viable cells were determined for over 7 days. The number of living cells did not significantly differ between H1-infected and noninfected cells at all time points (Table 1) . Therefore, H1 virus did not kill these immune cells to significant To assess induction of apoptosis, FACScan analysis for Annexin V was performed. For H1 protein detection, immunoblots with NS1 protein antibody were quantified by imaging. For transgene transduction, cells were infected with hH1D1600luc and quantified by luminometer (mean of three independent measurements). As standard, the NS1 protein expression and luciferase activity from H1-susceptible NB-E cells were set at 100%.
extents. The harmlessness of H1 was further confirmed by LDH activities 1-3 days p.i. In sharp contrast to SK29-Mel-1 cells with very high LDH levels, no different LDH levels between H1 virus-infected and noninfected immune cells were observed (data not shown). Again, H1-treated immature APC and CTL did not show evidence of apoptosis determined by FACScan analysis (Table 1) . To ascertain that virus gene expression did not occur, the luciferase activity was determined after recombinant hH1D1600luc infection. 8 Here, luciferase expression of human immune cells was comparable with background levels, only with the exception of EBV-transformed B cells and phytohemagglutinin-activated PBMC with minor luciferase activity (data not shown). These results are important preclinical data with respect to its potential use of H1 as antitumor agent, even if this analysis of the refractoriness of human immune cells is still incomplete for human clinical trials. So far, H1 was seldom pathogenic and infected humans without any apparent clinical consequences. 8, 10 Furthermore, this refractoriness to H1-induced killing cannot simply be attributed to the nondividing status, since the CTL were long-term cultures under antigen restimulation and these conditions allowed the cells to traverse the S-phase, a prerequisite for H1 to replicate and to become cytocidal. 8, 9 To explore the influence of H1 infection on the immunogenicity of tumor cells, the expression of HLA class I, and CD80 and CD86 costimulatory molecules was However, no such changes could be observed. As HSPs can also be detected after a significant stress had been applied upon the cell, we analyzed the constitutive and inducible form of HSP70 after H1 infection. In SK29-Mel-1 cells, the level of constitutive HSP73 did not change during the observation period (Fig  1b) . Like many other tumor cells, these cells displayed high basal HSP72 levels possibly as a tumor cell-specific protection mechanism to counteract transformationassociated death programs or to increase resistance to cytotoxic factors. 4, 5, 7 The intracellular levels of the inducible HSP72 dropped from day 2 p.i. onwards in H1-infected SK29-Mel-1 cells analyzed by immunoblots and imaging technique. The reduced HSP72 levels could be observed for both, cytosolic and nuclear protein extracts (data not shown). In parallel, the HSP72 levels in the culture media were increased, which were higher and prolonged compared with the positive controls consisting of HSP72 release after a standard heat-shock treatment (Fig 1c) . Moreover, the cellular loss of HSP72 preceded the typical apoptotic features when the results of FACscan, Western blotting and HSP70 ELISA were compared.
So far, the postulated mechanisms of HSP72 release remain to be elucidated in these H1-induced apoptotic SK 29-Mel-1 cells. Since H1 and parvovirus-derived vectors may overcome HSP-related and other apoptotic resistance mechanisms, they may be of therapeutic benefit for tumors which are more apoptosis-resistant than their untransformed counterparts. 8, 9 Furthermore, it is unknown whether H1-induced cell killing and its concomitant HSP72 release also promote the loading and maturation of APCs and by this means trigger tumorspecific immune responses. [4] [5] [6] [7] Experiments have been initiated in the laboratory to answer this intriguing question.
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